Oncology

The current study found no link between personal use of permanent hair dye and the risk of most cancers or cancer-related mortality.

The FDA also granted priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

In a virtual symposium titled Clinical Updates in Extensive-Disease Small Cell Lung Cancer: A Primer for Pharmacists Caring for Patients, 2 expert speakers discussed pivotal changes in the treatment landscape for small cell lung cancer.

A patient has Lynch syndrome, a hereditary condition that puts young people at high risk for colon cancer.

In a Pharmacy Times® webcast, Katie Culos, PharmD, BCOP, a specialist in cellular therapy and hematology discussed with Katherine Lin, PharmD, BCPS, BCOP the many policies and procedures that have been implemented during the COVID-19 pandemic by providers for cancer care.

A first-in-class targeted therapy, VB-111 is administered by intravenous infusion once every 6 to 8 weeks.

Many patients battling cancer are in dire need of support, encouragement, and care coordination.

Optimizing the best pharmaceutical agent while minimizing adverse effects is paramount in patients with cancer-associated venous thromboembolism.

Patients may have many questions before receiving CAR T-cell therapy, so accurate counseling is vital to their support.

At the Smilow Cancer Hospital, oncology pharmacists play an important role in the delivery of care for patients with cancer.

Despite an ongoing long-term debate, no link was found between cancer and the use of ACE inhibitors, beta blockers, and other common antihypertensive drugs.

A recent study demonstrated the safety and clinical activity of E7 TCR-T cells in the treatment of highly refractory metastatic HPV- 16+ cancers.

Oral chemotherapy may be an important option for patients during the COVID-19 pandemic, as it would allow them to receive treatment at home.

Study results have demonstrated that pharmacists are effective partners in improving care, reducing cost, and avoiding drug complications for patients with cancer.

Current advances in the analysis of the mutational status of different genes are providing investigators insights into new treatment pathways that can improve outcomes for patients.

Women who typically have a better prognosis in the primary breast cancer setting experienced worse survival after a second primary breast cancer.

Despite improvements in the understanding and treatment of chemotherapy-induced nausea and vomiting (CINV), nausea and emesis continue to be a distressing adverse event for patients.

Targeted photodynamic therapy has garnered increasing attention… because of its ability to treat tumors without surgery, chemotherapy, or radiation.

This activity is supported by an educational grant from Merck Sharp & Dohme Corp..

A new medication for certain rare blood cancers has now become available through a limited distribution with AllianceRx Walgreens Prime.

Pharmacists should refer patients to a health care provider if any symptoms could be indicative of a GIST.

Challenges and impact of rare diseases are faced by pharmacy stakeholders.

The FDA has approved a liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for rucaparib tablets.

Targeted radiotherapy amounted to fewer deaths over a 5-year follow-up period among patients with breast cancer.

Researchers have found that gene expression associated with aging was higher in young cancer survivors who are frail and in young patients with cancer following their treatment with chemotherapy.

Patient assistance programs are often the difference between accessing the drug and increasing abandonment rate.

PTCE, the industry-leading continuing pharmacy education provider, becomes sole provider for association’s 3 major meetings through 2021.

In addition to clinical procedures, some support groups for patients with breast cancer were also canceled as a result of the COVID-19 pandemic.

The increasing prevalence of oral oncolytics use, further accelerated by COVID-19, heightens the need for strong patient-pharmacist treatment coordination.

The researchers found that an ILI aimed at weight loss lowered incidence of obesity-related cancers by 16% in adults with overweight or obesity and T2D